

Quick Reference for the Treatment of Acute Agitation

Goals of pharmacologic therapy of acute agitation:

- Produce calming effect quickly without excessive sedation
- Provide early treatment of underlying psychosis
- Minimize treatment-related adverse events
- Assure patient and staff safety

Options for Management of Acute Agitation with Intramuscular Therapy



Clinical Pearls

- For psychotic agitation, if initial antipsychotic is ineffective, addition of a benzodiazepine is preferred over additional doses of antipsychotic. However, do not combine IM olanzapine with IM lorazepam due to the risk of respiratory depression.
- If appropriate, offer oral medication first and incorporate the patient in the medication decision.
- Rule-out possible causes of agitation:
 - Medical complications (ie. hyper- or hypoglycemia, electrolyte disturbance, renal or hepatic failure, thyroid or adrenal disorders, Wernicke's encephalopathy, hypotension, heart failure, neurologic disorders [stroke], infection)
 - Substance intoxication or withdrawal
 - Medication causes (ie. steroids, anticholinergics, barbiturates, amphetamines, antipsychotic-induced akathisia)
- Allow adequate time for clinical response between doses (see table on page 2).
- After treatment with IM agents, monitor vitals and clinical status at regular intervals.
- Second generation antipsychotic agents have a lower risk of EPS than haloperidol but have demonstrated similar and comparable efficacy in treating acute agitation.
- For psychotic agitation, combining a benzodiazepine and a typical antipsychotic is more effective than typical antipsychotic monotherapy and may allow for decreased doses of the antipsychotic medication.
- Concurrent administration of diphenhydramine with haloperidol is not recommended as it requires two separate injections and increases the risk of over sedation and interactions with other medications.
- Use lower starting and maximum doses in the elderly and child and adolescent population.



Comparison of IM Treatment Options

Medication	Typical Dose	Max Single Dose	Repeat Dosing	Max Adult Dose/ 24hrs	Time to Onset	Time to Peak Cp	Half-life (hours)
Lorazepam	1-2mg	4mg	0.5 hour	12mg	20-30 min	1-3 hr	14
Haloperidol lactate	5-10mg	10mg	1 hour	40mg	30-60 min	20 min	20
Chlorpromazine ^{1,2}	25-50mg	100mg	2 hours	400mg		1-4 hr	2 -30
Ziprasidone ²	10mg 20mg	20mg	2 hours 4 hours	40mg	15 min	1 hr	2-5
Olanzapine ^{2,3}	10mg	10mg	2 hours ³	30ma	15-45 min	15-45 min	30

¹IM chlorpromazine is not recommended for the management of acute agitation. There are significant risks of QTc prolongation, hypotension, reduction in seizure threshold, a slow onset of effect, and risk of local irritation at the injection site.

² Reconstitution required before administration.

³Monitor for orthostatic hypotension prior to administration of repeat dosing.

Comparison of Oral Agents for Acute Agitation

Medication	Typical Dose	Repeat Dosing (hours)	Max Adult Dose/ 24hrs	Estimated Time of Onset (minutes)	Time to Peak Cp (hours)	Half-life (hours)
Lorazepam	1-2mg	2	10mg	20-30	2	12
Haloperidol	5-10mg	1	40mg	30	2-6	14-37
Chlorpromazine ¹	25- 50mg	×	2000mg	×	2.8	6
Ziprasidone ²	20- 40mg	×	240mg	×	6-8	7
Olanzapine ODT	5-10mg	2	30mg	≤ 60	6	30
Risperidone m-tab Risperidone soln. ³	1-2mg 1-2mg	2	8mg	× ≤ 60	~1	20

×Not studied as a treatment for acute agitation and aggression.

¹Chlorpromazine is expressed as having limited, poor, and outdated data as treatment for acute agitation. ²Oral ziprasidone absorption is significantly decreased without administration with a meal (250-500 calories). ³When given in combination with IM lorazepam.

References

- Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Sys Rev. April 2010. 14(4): CD007445. Doi:
 - 10.1002/14651858.CD007445.pub2
- Calver L, Drinkwater V, Gupta R, et al. Droperidol v haloperidol for sedation of aggressive behavior in acute mental health: randomized controlled trial. British Journal of Psychiatry. March 2015. 206(3):223-228. Doi: 10.1192/bjp.bp.114.150227
- Clinton J, Sterner S, Stelmachers Z, et al. Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med. March 1987. 16(3): 319-322.
- Gomez S, Dopheide J. Antipsychotic selection for acute agitation and time to repeat use in a psychiatric emergency department. J Psychiatr Pract. November 2016. 22(6): 450-458. Doi: 10.1097/PRA.00000000000186
- Hatta K, Kawabata T, Yoshida K, et al. Olanzapine orally disintegrating tablet vs risperidone oral solution in the treatment of acutely agitated psychotic patients. General Hospital Psychiatry. July-August 2008. 30(4): 367-371. Doi: 10.1016/j.genhosppsych.2008.03.004

Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com.

Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: http://www.micromedexsolutions.com.

- San L, Arranz B, Querejeta I, et al. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psy. December 2006. 21(8):539-543. Doi: 10.1016/jeurpsy.2006.03.005
- Tulloch K, Zed P. Intramuscular Olanzapine in the Management of Acute Agitation. Annals of Pharmacotherapy. December 2004. 38(12):2128-2135. Doi: 10.1345/aph.1E258



Wilson MP. The psychopharmacology of agitation: consensus statement of the American association for emergency psychiatry project Beta psychopharmacology workgroup. Western Journal of Emergency Medicine. 2012;13(1):26-34.

Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine, and quetiapine versus haloperidol in psychotic agitation. Progress in Neuro-Psychopharmacology and Biological Psychiatry. February 2008. 32(2): 405-413. Doi: 10.1016/j.pnpbp.2007.09.007